Free Trial
NASDAQ:PRFX

PainReform Q4 2025 Earnings Results & Report

PainReform logo
$0.69 -0.09 (-11.83%)
As of 02:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

PainReform beat analyst earnings expectations in its Q4 2025 results, released April 6, 2026. The company reported EPS of -$0.9850 versus the -$612.00 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens

PainReform EPS Results

Actual EPS
-$0.9850
Consensus EPS
-$612.00
Beat/Miss
Beat by +$611.0150
One Year Ago EPS
N/A

PainReform Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

PainReform Q4 2025 Earnings FAQ

PainReform (NASDAQ:PRFX) reported earnings of -$0.9850 per share for Q4 2025, beating the consensus estimate of -$612.00. The report was announced on Monday, April 6, 2026.

PainReform Earnings Headlines

My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
See More PainReform Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PainReform? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PainReform and other key companies, straight to your email.

About PainReform

PainReform (NASDAQ:PRFX) (NASDAQ: PRFX) is a clinical-stage specialty pharmaceutical company focused on developing treatments for acute post-operative pain. The company’s work is aimed at addressing pain experienced after surgical procedures and reducing reliance on conventional short-acting analgesics.

PainReform’s lead product candidate, PRF-110, is an extended-release formulation of ropivacaine, a local anesthetic. Designed for administration at the surgical site, PRF-110 is intended to provide prolonged pain relief during the days following surgery. The company has evaluated the product in clinical programs involving procedures such as bunionectomy and hernia repair.

Founded in Israel, PainReform has conducted its product development activities through clinical and regulatory programs targeting the U.S. market. As a development-stage company, its business remains centered on advancing PRF-110 and its drug-delivery technology rather than marketing an established portfolio of commercial products.

View PainReform Profile